[1] Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 2008, 7(7), 1851-1863. DOI:
10.1158/1535-7163.MCT-08-0017[2] Roper J, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One, 2011, 6(9), e25132. DOI:
10.1371/journal.pone.0025132[3] Lee M, et al. Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas. Clin Cancer Res. 2015 Jul 15;21(14):3204-15. DOI:
10.1158/1078-0432.CCR-15-0288[4] KATHRIN ZITZMANN . Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease[J]. Cancer letters, 2010, 295 1: Pages 100-109. DOI:
10.1016/j.canlet.2010.02.018[5] VIOLETA SERRA. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.[J]. Cancer research, 2008: 8022-8030. DOI:
10.1158/0008-5472.can-08-1385[6] CHRISTIAN R SCHNELL. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.[J]. Cancer research, 2008: 6598-6607. DOI:
10.1158/0008-5472.can-08-1044[7] ROMINA MARONE. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.[J]. Molecular Cancer Research, 2009, 7 4: 601-613. DOI:
10.1158/1541-7786.mcr-08-0366[8] SASKIA M BRACHMANN. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2009: 22299-22304. DOI:
10.1073/pnas.0905152106
